Back to discover

Protein / target

Protein kinase C beta type

Encoded byPRKCBP05771Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Diacylglycerol-dependent serine/threonine kinase

Strongest disease association

Colitis, Ulcerative

Via encoding gene PRKCB · Genetic evidence · score 0.72

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin si…

View complete UniProt function annotation

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity (PubMed:11598012). Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (AR)-dependent transcription, by being recruited to AR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. Participates in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1 (PubMed:25982116). Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity). Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription (PubMed:19176525). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231)

Subcellular location

CytoplasmNucleusMembrane
Domains and Gene Ontology detail (46)

Domains & features

C2Protein kinaseAGC-kinase C-terminal

Gene Ontology

  • Ccalyx of Held
  • Ccytoplasm
  • Ccytosol
  • Cextracellular exosome
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane
  • Cpresynaptic cytosol
  • Cspectrin
  • FATP binding
  • Fcalcium channel regulator activity
  • Fcalcium,diacylglycerol-dependent serine/threonine kinase activity

671 aa · 77 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GOGrowth-factor signallingGOKinase signallingUniProt · GOTranscriptional regulationUniProt · GOImmune signallingGO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-pro…
  • ·lipoprotein transport

Growth-factor signalling

  • ·positive regulation of vascular endothelial growth factor receptor signaling pathway

Kinase signalling

  • ·Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-pro…
  • ·calcium,diacylglycerol-dependent serine/threonine kinase activity
  • ·diacylglycerol-dependent serine/threonine kinase activity
  • ·histone H3T6 kinase activity

Transcriptional regulation

  • ·Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-pro…
  • ·transcription coactivator activity
  • ·DNA-templated transcription
  • ·regulation of transcription by RNA polymerase II

Immune signalling

  • ·adaptive immune response
  • ·B cell activation
  • ·B cell receptor signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

midostaurin
ApprovedInhibitor

Protein kinase C (PKC) inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PRKD3, PRKCI, PRKCA +7 more · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRKCB

Gene-level evidence surfaced through the gene PRKCB that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Colitis, Ulcerative
0.75Well supported

Genetic evidence dominant · Open Targets 0.46

Leukemia, Myeloid, Acute
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.59

Inflammatory Bowel Diseases
0.68Moderately supported

Genetic evidence dominant · Open Targets 0.42

Neoplasms
0.62Moderately supported

Clinical evidence dominant · Open Targets 0.44

Lymphoma, Large B-Cell, Diffuse
0.54Moderately supported

Clinical evidence dominant · Open Targets 0.36

View evidence synthesis (5)
Colitis, UlcerativeWell supported
0.75
agreement 0.640.86
Genetic88%Clinical11%RNA expression1%

Open Targets aggregate 0.46 · 3 independent evidence families

Leukemia, Myeloid, AcuteModerately supported
0.74
agreement 0.620.86
Clinical77%Somatic mutation23%Literature1%

Open Targets aggregate 0.59 · 3 independent evidence families

Inflammatory Bowel DiseasesModerately supported
0.68
agreement 0.550.82
Genetic98%Literature3%

Open Targets aggregate 0.42 · 2 independent evidence families

NeoplasmsModerately supported
0.62
agreement 0.500.74
Clinical60%Somatic mutation25%Literature14%

Open Targets aggregate 0.44 · 3 independent evidence families

Lymphoma, Large B-Cell, DiffuseModerately supported
0.54
agreement 0.420.66
Clinical55%Somatic mutation29%Literature16%

Open Targets aggregate 0.36 · 3 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Leukemia, Myeloid, Acute0.59
Colitis, Ulcerative0.46
Neoplasms0.44
Inflammatory Bowel Diseases0.42
Lymphoma, Large B-Cell, Diffuse0.36

Drug development

7 compounds recorded · 1 approved · 6 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (7)
CEP-2563Phase 1
ENZASTAURINPhase 3
UCN-01Phase 2
SOTRASTAURINPhase 2
RUBOXISTAURINPhase 3
GSK-690693Phase 1
MIDOSTAURINApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and High-Quality Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (8)
SM · Approved DrugSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

hyperglycemiaClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  2. New publication2017-07-24
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

    Leukemia · 2018 · 109 citations · Europe PMC · via midostaurin

  3. New publication2016-06-01
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

    The New England journal of medicine · 2016 · 371 citations · Europe PMC · via midostaurin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.